The answer so far
In a large oral AOD-9604 study described by the US FDA, weight loss was not statistically significantly different from placebo at the primary assessment. That result concerns a particular oral formulation, population and study; it does not establish the benefit or safety of a different product or injection. The complete study report was not available for appraisal here.12
On this page
Why does this peptide attract interest?
AOD-9604 is a synthetic peptide related to a fragment of growth hormone. It has been marketed with claims about fat burning or weight loss. The appealing idea is that a fragment might affect fat without reproducing every effect of the full hormone. That idea needs to be tested in people: a name, an animal finding or a short-term metabolic change is not a clinical weight-loss result. Start with what fat burning and fat loss mean.12
What was the OPTIONS study?
FDA’s 2024 advisory presentation describes a company-sponsored, randomised, double-blind comparison of an oral AOD-9604 preparation and placebo in adults with obesity. Of 536 people enrolled, 502 were included in the randomised comparison. Participants also had a dietitian-supervised diet and exercise programme. Treatment lasted 24 weeks; the primary weight-loss assessment was at 12 weeks. The study asked about a particular oral preparation, not all products sold under the same name.
The FDA briefing also reports a four-week placebo run-in before the 24-week treatment period.
A 2013 company-funded safety summary calls this trial METAOD006 and reports 534 enrolled; both sources report 502 randomised. The reason for the difference in enrollment counts is not established. The safety summary gives some design and safety details but is not a complete report of weight-loss efficacy.315
What does “not statistically significant” mean here?
FDA reported no statistically significant difference in weight loss between the oral AOD-9604 and placebo groups. That is not proof that the groups were exactly identical, nor evidence that a different preparation works. A comparison matters because changes can occur alongside diet, activity or other factors in both groups. The presentation summarised company-reported results; FDA said it did not find detailed study design and preliminary efficacy results in the published medical literature. We have not independently reviewed a complete trial report.3
Why do some accounts cite a positive result?
FDA also described a separate 2005 conference abstract involving 300 adults. The abstract’s authors reported a weight-loss difference for some groups, but the regulator identified sparse numerical and methodological details and an unclear clinical meaning. An abstract is a brief report, not necessarily a complete trial publication. The older report and the later OPTIONS study are different pieces of evidence; neither should be described as a guarantee for an online product.3
Does the oral result answer the injection question?
No. Route and complete formulation can change exposure, manufacturing and safety questions. The oral comparison does not establish that an injectable product works or is safe, and it cannot rule out every possible effect of a different preparation. FDA described unresolved questions about injectable AOD-9604, including ingredient characterisation and possible immune reactions. See why the route matters and the AOD-9604 profile.1
What evidence would answer a practical claim?
Look for the exact product and route, a relevant population, a placebo or other meaningful comparison, a prespecified outcome, and sufficient follow-up for benefits and harms. Weight, changes in body-fat measurements and improvements in health are different outcomes. The weight and peptide map connects this question to appetite medicines and tesamorelin without treating them as equivalent.
For the separate joint question, see what the AOD-9604 cartilage study actually showed.34
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- AOD-9604 related bulk drug substances: FDA advisory committee briefingUS Food and Drug Administration · 2024 US regulator briefing; obesity evaluation and search limitations
- Dietary Supplements for Weight Loss: Health Professional Fact SheetNIH Office of Dietary Supplements · Authoritative evidence overview; supplements, not peptide medicines
- Pharmacy Compounding Advisory Committee presentation: AOD-9604U.S. Food and Drug Administration · Regulator advisory presentation summarising sponsor-reported trial; United States; December 2024
- Overweight and obesity in adultsNational Institutes of Health · Public health overview
- Safety and Tolerability of the Hexadecapeptide AOD9604 in HumansJournal of Endocrinology and Metabolism · Published safety summary of six trials